On-target activity of neoadjuvant cixutumumab and combined androgen deprivation therapy for high-risk prostate cancer: A phase II trial. Background: Degarelix, a GnRH receptor antagonist inducing ...
As a result, researchers have explored less invasive options that aim to treat the cancer while preserving quality of life. One such approach is TULSA, which uses real-time MRI guidance to deliver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results